Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zai Lab Limited (ZLAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures related to its American Depositary Shares listed on the Nasdaq Global Market. Zai Lab is a research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on oncology, immunology, neuroscience, and infectious disease. Its SEC filings offer detailed information on financial performance, risk factors, capital structure, and key corporate agreements.
Through this page, users can review Zai Lab’s current reports on Form 8-K, which have covered topics such as quarterly financial results and the entry into a material definitive agreement for a renminbi-denominated revolving credit facility to support working capital needs in mainland China. These filings also describe how certain information, including earnings press releases furnished as exhibits, is treated for purposes of the Securities Exchange Act of 1934.
In addition to 8-Ks, investors can use this page as a starting point to locate Zai Lab’s annual and other periodic reports filed with the SEC, which discuss its dual-engine strategy, commercial portfolio in China, and global research and development programs. For a biopharmaceutical company like Zai Lab, these documents are important for understanding product revenue sources, R&D investment, licensing arrangements for medicines such as VYVGART, NUZYRA, ZEJULA, AUGTYRO, and COBENFY, and the financial implications of its pipeline.
Stock Titan enhances the raw filing data with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items such as new credit facilities, changes in operations, or significant clinical and commercial milestones referenced in the filings. Real-time updates from EDGAR, combined with organized access to forms including 8-K and other SEC documents, allow users to monitor ZLAB’s regulatory reporting and corporate actions efficiently.
Zai Lab executive Yajing Chen filed Form 144 indicating intent to sell 2,675 American Depositary Shares with an aggregate market value of $96,651.76. The sale is scheduled for June 26, 2025, through Fidelity Brokerage Services on NASDAQ.
The shares were acquired on June 25, 2025, through restricted stock vesting as part of compensation. The filing notes that the sale is partially intended to cover tax obligations from the vested equity award distribution.
Previous trading activity by Chen in the past 3 months includes:
- June 2, 2025: Sold 9,618 shares for $288,540.00
- April 4, 2025: Sold 924 shares for $30,592.25
- April 2, 2025: Sold 5,280 shares for $189,521.38
The company has approximately 486.85 million shares outstanding. The filing was signed by Wade Moss as a representative of Fidelity Brokerage Services, acting as attorney-in-fact for Chen.
Zai Lab Director and Officer Ying Du filed Form 144 indicating a proposed sale of 23,669 American Depositary Shares with an aggregate market value of $855,196.47 through Fidelity Brokerage Services. The shares were acquired through restricted stock vesting on June 25, 2025, as part of compensation.
Notable recent trading activity by Du includes:
- Multiple large sales in May 2025 totaling 196,389 shares with combined proceeds of $5.68 million
- Two smaller sales in April 2025 totaling 8,753 shares for $305,978
The filing indicates the sale is partially intended to cover tax obligations from vested equity awards. Du has certified no knowledge of undisclosed material adverse information regarding Zai Lab's operations. The company has 486.85 million shares outstanding, and the proposed sale represents approximately 0.005% of total shares.
Peter Wirth, Director at Zai Lab (ZLAB), received a grant of 10,831 American Depositary Shares (ADS) on June 18, 2025. Key details of the transaction:
- Transaction Type: Acquisition of restricted shares
- Purchase Price: $0 (granted as compensation)
- Vesting Schedule: Full vesting on June 18, 2026, contingent on continued board service
- Post-Transaction Holdings: 393,750 ADSs held directly
Each ADS represents ten ordinary shares of Zai Lab. The shares were granted as part of director compensation and are subject to a one-year vesting period. This Form 4 filing was submitted by Bruce Blefeld as attorney-in-fact on June 23, 2025.
SEC Form 4 Overview: On 18 June 2025, Zai Lab Ltd (ticker ZLAB) granted Director Michel Vounatsos an equity award of 10,831 American Depositary Shares (ADSs) at a cost basis of $0. Each ADS represents ten ordinary shares. The award consists of restricted shares that will vest in full on 18 June 2026, contingent on his continued board service. Following this grant, Vounatsos’ direct beneficial ownership increased to 50,416 ADSs. No derivative securities or sales were reported.
The filing signals routine director compensation aimed at aligning board incentives with shareholder interests; it does not disclose any purchases or sales on the open market and carries no immediate cash impact for the company.
Leon O. Moulder Jr., Director of Zai Lab, received a grant of 10,831 American Depositary Shares (ADS) on June 18, 2025. Key details of the transaction:
- The shares were acquired at $0 cost as restricted stock compensation
- The restricted shares will fully vest on June 18, 2026, contingent on Moulder's continued service on the board
- Following the transaction, Moulder directly owns 72,602 ADSs
- Each ADS represents 10 ordinary shares of Zai Lab
This Form 4 filing discloses standard equity-based director compensation, suggesting continued alignment between board member and shareholder interests. The one-year vesting period serves as a retention mechanism for the director's services.
On 06/18/2025, Zai Lab Limited (ticker: ZLAB) reported a director share transaction in a Form 4 filing. Director Richard Gaynor received 10,831 American Depositary Shares (ADS)—each ADS represents ten ordinary shares—under transaction code A (acquisition) at a price of $0, indicating a restricted share award rather than an open-market purchase.
After the grant, Gaynor’s total beneficial ownership rose to 54,899 ADS. The award will vest in full on 06/18/2026, contingent upon his continued board service. No derivative securities were involved and no shares were sold. The filing underscores ongoing equity-based compensation to align director incentives with shareholder interests, with no immediate cash impact on Zai Lab’s financials.
Form 4 Overview – Zai Lab Ltd (ZLAB)
The filing discloses that director Dr. John D. Diekman received a grant of 10,831 American Depositary Shares (ADSs) of Zai Lab on 18 June 2025. Each ADS represents ten ordinary shares. The grant was recorded with a transaction code “A”, indicating an acquisition.
Key transaction terms
- Type: Restricted stock award
- Cost basis: $0 per ADS (no cash payment required)
- Vesting: Shares vest in full on 18 June 2026, contingent on Dr. Diekman’s continued board service.
- Post-transaction holdings: 99,769 ADSs held directly after the award.
No derivative securities, sales, or option exercises were reported in this filing. The grant appears to be routine director equity compensation and does not stem from a Rule 10b5-1 trading plan.
Investor takeaway
The award modestly increases insider ownership and signals continued board alignment with shareholders, but it is not a market purchase. Because the shares are subject to a one-year vesting schedule and were issued at no cost, the filing is generally considered neutral‐to-positive in sentiment and immaterial to near-term valuation.
Form 4 filing overview – Zai Lab Limited (ZLAB)
Director William Lis reported two transactions involving American Depositary Shares (ADS), each ADS representing ten ordinary shares:
- 18 Jun 2025 – Grant of 10,831 ADSs recorded as an acquisition at $0 cost. These are restricted shares that will vest in full on 18 Jun 2026, contingent upon Mr. Lis’s continued board service.
- 20 Jun 2025 – Sale of 13,814 ADSs executed under a Rule 10b5-1 trading plan adopted on 4 Mar 2025, at a reported price of $35.67 per ADS.
After the transactions, Mr. Lis’s direct beneficial ownership declined from 48,920 to 35,106 ADSs, a net reduction of 13,814 ADSs before taking the un-vested restricted shares into account.
No derivative securities were reported. There were no indications of additional equity incentives, option exercises, or open-market purchases besides the restricted-share grant.
Investor take-away: Although the director received a one-year restricted-share grant, the subsequent larger sale results in a modest net decrease in his immediately available holdings, possibly signalling limited short-term confidence or liquidity needs. The sale was pre-planned under Rule 10b5-1, which mitigates concerns of opportunistic timing.
Form Type: 4 – Statement of Changes in Beneficial Ownership for Zai Lab Ltd. (ZLAB), filed 23 Jun 2025.
Key event: Director Nisa Leung received 10,831 American Depositary Shares (ADSs) on 18 Jun 2025 at a reported price of $0, indicating a restricted stock grant rather than an open-market purchase. Each ADS equals ten ordinary shares.
Vesting schedule: The entire award vests on 18 Jun 2026, conditional upon Ms. Leung’s continued board service.
Post-transaction ownership: Direct beneficial holdings increase to 73,926 ADSs. No derivative securities were involved.
Ownership clarification: Shares previously attributed to QM11 Limited have been removed because the director no longer holds a position conferring beneficial ownership, aligning the disclosure with current circumstances.
Implications: The grant modestly strengthens director-shareholder alignment but does not materially affect ZLAB’s capital structure or valuation.